Neuropsychopharmacology

TABLE 1

FROM:

Long-Term Effects of Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant Depression: Evidence for Sustained Efficacy

Bettina H Bewernick, Sarah Kayser, Volker Sturm and Thomas E Schlaepfer

BACK TO ARTICLE

Table 1. Demographic and Clinical Characteristics

VariableMeanSDRespondersNon-responders
   MeanSDMeanSD
Age at implant (years)48.3611.0845.612.950.69.8
Sex (% female)33 60 16.6 
Duration of education (years)14.302.3614.252.514.32.5
Retirement because of depression (% retired)90.00 80 100 
Length of current episode (years)9.267.645.983.5129.3
Number of previous episodes (lifetime)a1.29 1.750.90.60.5
Age at onset (years)32.5512.4134.814.430.611.4
Time since diagnosis of affective disorder (years)17.459.9112.64.721.511.6
Lengths of previous hospitalizations (months)20.1811.2418.410.221.612.7
Number of antidepressive pharmaceuticals at implant4.361.213.814.81.1
Number of past medical treatment courses22.187.73195.524.88.7
Number of medications included in formula13.825.3412415.36.1
Mean total of ATHF scoreb40.2715.2438.614.341.617.1
Mean ATHF score and SD3.180.403.40.530
Average number of treatment trials with ATHF greater than or equal to37.913.367.63.38.13.6
Past ECT/MST21.098.4822.28.720.18.9
Psychotherapy (h)263.64263.88185.2143.8329333.8
Suicide attempts (% of patients preoperative)27 20 33.3 

a Fifty percent of patients did not have separate episodes.

b Modified antidepressant treatment history form (ATHF). A score of ‘3’ is the threshold for considering a trial adequate and the patient resistant to the treatment.

 Mean and SD, if applicable, are reported.

BACK TO ARTICLE